PDF herunterladen
Am J Perinatol 2019; 36(06): 647-652
DOI: 10.1055/s-0038-1673651
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Are Women with a History of Low PAPP-A at Risk for Adverse Perinatal Outcomes in a Subsequent Pregnancy?

Kelly B. Zafman
1   Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
,
Chloe S. Getrajdman
1   Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
,
Melanie K. Arnold
1   Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
,
Joanne L. Stone
1   Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
› Institutsangaben
Weitere Informationen

Publikationsverlauf

13. Juni 2018

29. August 2018

Publikationsdatum:
18. Oktober 2018 (online)

    Lizenzen und Reprints

Abstract

Objective To determine if patients with a history of low pregnancy-associated plasma protein A (PAPP-A) in an initial pregnancy are at higher risk for adverse obstetric outcomes in a subsequent pregnancy.

Study Design This was a retrospective cohort study in patients who underwent first trimester screening for PAPP-A in two consecutive pregnancies. Two groups were examined: patients who had low PAPP-A in the first pregnancy followed by normal PAPP-A in the second pregnancy and patients who had recurrent low PAPP-A. Maternal and neonatal outcomes were compared between the groups, with the primary outcome being intrauterine growth restriction (IUGR) or preeclampsia.

Results A total of 124 patients were included, representing 248 pregnancies. Ninety-two (74.2%) patients had normal PAPP-A in the second pregnancy, and 32 (12.9%) patients had recurrent low PAPP-A. Patients with recurrent low PAPP-A had a higher rate of IUGR or preeclampsia compared with patients with normal PAPP-A in the second pregnancy but this was not significantly different (12.5 vs. 10.9%, p = 0.51). There were no significant differences for all other outcomes.

Conclusion Among patients with a history of low PAPP-A, patients with normal PAPP-A in the subsequent pregnancy have a similar risk of adverse neonatal outcomes compared with patients with recurrent low PAPP-A.

Keywords

first trimester screening - PAPP-A - preeclampsia - intrauterine growth restriction - maternal and neonatal outcomes
 

  • References

  • 1 Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ 2013; 347: f6564
    CrossrefPubMedGoogle Scholar
  • 2 Sharma D, Shastri S, Sharma P. Intrauterine growth restriction: antenatal and postnatal aspects. Clin Med Insights Pediatr 2016; 10: 67-83
    PubMedGoogle Scholar
  • 3 Barrett SL, Bower C, Hadlow NC. Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes. Prenat Diagn 2008; 28 (01) 28-35
    CrossrefPubMedGoogle Scholar
  • 4 Scott F, Coates A, McLennan A. Pregnancy outcome in the setting of extremely low first trimester PAPP-A levels. Aust N Z J Obstet Gynaecol 2009; 49 (03) 258-262
    CrossrefPubMedGoogle Scholar
  • 5 Laursen LS, Overgaard MT, Søe R. , et al. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett 2001; 504 (1-2): 36-40
    CrossrefPubMedGoogle Scholar
  • 6 Smith GC, Crossley JA, Aitken DA. , et al. First-trimester placentation and the risk of antepartum stillbirth. JAMA 2004; 292 (18) 2249-2254
    CrossrefPubMedGoogle Scholar
  • 7 Fox NS, Chasen ST. ; S. FN. First trimester pregnancy associated plasma protein-A as a marker for poor pregnancy outcome in patients with early-onset fetal growth restriction. Prenat Diagn 2009; 29 (13) 1244-1248
    CrossrefPubMedGoogle Scholar
  • 8 Baschat AA, Cosmi E, Bilardo CM. , et al. Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol 2007; 109 (2 Pt 1): 253-261
    CrossrefPubMedGoogle Scholar
  • 9 Bujold E, Roberge S, Lacasse Y. , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 (2 Pt 1): 402-414
    CrossrefPubMedGoogle Scholar
  • 10 Roberge S, Giguère Y, Villa P. , et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 2012; 29 (07) 551-556
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 11 Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31 (01) 7-15
    CrossrefPubMedGoogle Scholar
  • 12 Hernández-Díaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ 2009; 338: b2255
    CrossrefPubMedGoogle Scholar
  • 13 American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122 (05) 1122-1131
    CrossrefPubMedGoogle Scholar
  • 14 Rolnik DL, Wright D, Poon LC. , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622
    CrossrefPubMedGoogle Scholar